Following publication of the original article [1], the authors noticed that two corrections were not implemented during the production process. The original article [1] has been corrected.
Following publication of the original article [1] , the authors noticed that two corrections were not implemented during the production process. The original article [1] has been corrected.
In Fig. 1b , the heading should read: Adjusted survival due to lack of effectiveness In Fig. 2b , the heading should read: Adjusted survival due to toxic adverse events In addition, the authors would like to update the legends of Figure 1 , 2, 3 and 4 to the following: Fig. 1 Drug survival rates due to lack of effectiveness in a non-adjusted cases and b adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs 
